Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBOV-515
- Development stage
- Preclinical
- Lead developer
- Vanderbilt University Medical Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**EBOV-515** is a human monoclonal antibody (mAb) isolated from Ebola virus survivors, designed as a pan-ebolavirus therapeutic. It targets the base region of the ebolavirus glycoprotein (GP), exhibiting potent neutralizing activity against Ebola virus (EBOV), Bundibugyo ebolavirus (BDBV), and Sudan ebolavirus (SUDV) with IC50 values ranging from 400 to 5,000 ng/mL. EBOV-515 demonstrates high efficacy in preclinical models, providing complete protection against lethal EBOV challenge in mice at doses as low as 1 mg/kg (especially the Fc-modified LALA-PG variant) and contributing to synergistic protection in nonhuman primates when combined with rEBOV-442. Its mechanism involves strong binding to cleaved GP (GPCL), inhibition of GP processing, and resistance to viral escape, positioning it as a promising candidate for post-exposure prophylaxis and treatment of ebolavirus disease.[1][4]
- Other names
- EBOV-515 IgG1EBOV515 IgG1EBOV 515 IgG1
02
Targets
GP base (Ebolavirus glycoprotein base region)
Beyond the preview
Go deeper on EBOV-515.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBOV-515.